Compare Mattel Inc (MAT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Sanofi SA — how do they compare? Mattel Inc trades at $15.03 (market cap $4.21B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 24.8× Mattel Inc's market cap, and Sanofi SA pays a 5.56% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| MAT | SNY | |
|---|---|---|
Market Cap | $4.21B | $104.57B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $52.34 |
52-Week Low | $13.05 | $41.33 |
Enterprise Value | $6.44B | $124.48B |
Dividend Yield | — | 5.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
